Patents Assigned to Rigel Pharmaceuticals
  • Patent number: 7220745
    Abstract: The present invention relates to substituted diphenyl heterocycle compounds and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the use of the compounds and/or compositions to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.
    Type: Grant
    Filed: May 15, 2003
    Date of Patent: May 22, 2007
    Assignee: Rigel Pharmaceuticals
    Inventors: Rajinder Singh, Dane Goff, John Partridge
  • Publication number: 20060051755
    Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding BRCA-1-Associated Protein-1 (BAP-1), Nuclear Protein 95 (NP95), Fanconi anemia group A protein (FANCA), DEAD/H box polypeptide 9 (DDX9), insulin-like growth factor 1 receptor (IGF1R), ubiquitin-conjugating enzyme E2 variant 1 (UBE2V1), aldehyde dehydrogenase, pyruvate kinase, glucose-6-phosphate dehydrogenase, HCDR-3, DEAD/H box polypeptide 21 (DDX21), serine threonine kinase 15 (ARK2), transmembrane 4 superfamily member 1, or ERCC1, which are involved in modulation of cell cycle arrest.
    Type: Application
    Filed: April 15, 2003
    Publication date: March 9, 2006
    Applicant: RIGEL PHARMACEUTICALS
    Inventors: Yasumichi Hitoshi, Yonchu Jenkins
  • Publication number: 20040180353
    Abstract: The present invention relates to regulation of the cell cycle. More particularly, the present invention is directed to nucleic acids encoding components of the ubiquitin ligation pathway, e.g., ubiquitin and ubiquitin-like molecules, E1, E2, and E3 proteins and their substrates, which are involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of the ubiquitin ligation pathway; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.
    Type: Application
    Filed: August 28, 2003
    Publication date: September 16, 2004
    Applicant: Rigel Pharmaceuticals
    Inventors: Robert Booher, Esteban Masuda, Valeria Ossovskaya, Brian Wong
  • Publication number: 20030195138
    Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding BAP-1, which is involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of BAP-1; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.
    Type: Application
    Filed: April 15, 2002
    Publication date: October 16, 2003
    Applicant: Rigel Pharmaceuticals
    Inventors: Yasumichi Hitoshi, Yonchu Jenkins